title: Alterations of growth fraction and DNA content in K562 cells by differentiating agents.
abstract: The growth fraction, estimated by the monoclonal antibody Ki-67 labeling, and DNA content, assessed by ethidium bromide staining, were determined simultaneously in K562 leukemic cells by flow cytometry. A multiparametric analysis enabled the fraction of the cell population with G1, S, and G2 + M contents in Ki-67-positive and Ki-67-negative cells to be evaluated. Butyric acid (BUT) was used as positive control. The fraction of Ki-positive cells decreased with the BUT concentration, while the proportion of cells with G1 DNA content increased only in the Ki-negative cells. Adriamycin, aclacinomycin A, and fagaronine induced differentiation, as assessed by benzidine staining and glycophorin A expression. These drugs decreased the fraction of Ki-positive cells by more than 50% for both anthracyclines and by 25% for fagaronine. Following treatment, Ki-negative cells displayed a G1, but also a G2 and a S DNA content in different proportions, indicating that induction of quiescent cells by differentiating agents is not a uniform process and is worthy of interest.
authors.affiliation: Institut Jean Godinot, GIBSA, Reims, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Gorisse
authors.forename: Y
authors.initials: Y
authors.lastname: Carpentier
authors.forename: P
authors.initials: P
authors.lastname: Joly
authors.forename: L
authors.initials: L
authors.lastname: Comoe
authors.forename: B
authors.initials: B
authors.lastname: Desoize
mesh_terms: D015250:Aclarubicin / Q000494:pharmacology; D000470:Alkaloids / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D053119:Benzophenanthridines; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002454:Cell Differentiation / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000187:drug effects*; D004317:Doxorubicin / Q000494:pharmacology; D006801:Humans; D019394:Ki-67 Antigen; D007938:Leukemia / Q000235:genetics*; D009687:Nuclear Proteins / Q000032:analysis; D010617:Phenanthridines; D018809:Proliferating Cell Nuclear Antigen; D014407:Tumor Cells, Cultured
chemical_list: D000470:Alkaloids; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D000970:Antineoplastic Agents; D053119:Benzophenanthridines; D002087:Butyrates; D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D009687:Nuclear Proteins; D010617:Phenanthridines; D018809:Proliferating Cell Nuclear Antigen; D020148:Butyric Acid; C002066:fagaronine; D015250:Aclarubicin; D004317:Doxorubicin